Levetiracetam IV

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Levetiracetam IV is one of 63 small molecule programs targeting Encephalopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EncephalopathyNot yet recruiting

SeizureActive, not recruiting

EncephalopathyPhase 3

Not yet recruiting

SeizurePreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Encephalopathy

#DrugCompanyPhaseTrials

Chronulac

SSolvay Pharmaceuticals

Approved

27 2

Golytely

Bayer

Approved

1 3

Zyloprim

Glucophage

1 5

Osmitrol

BB. Braun Medical Inc.

Approved

—6

Carnitor

LLeadiant Biosciences, Inc.

Approved

—7

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Approved

2 8

Alinia

RRomark Laboratories L.C.

Phase 3

4 9

PROCRIT

WWim Janssens

Phase 3

3 10

Citicoline

UUniversity of Texas Southwestern Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Encephalopathy

NCT06851078

Clinical

Trials by Indication[1]

Seizure1 trial

Levetiracetam Versus Phenobarbital in Benzodiazepines Unresponsive Paediatric Prolonged Seizures

Recruiting·MMinistry of Health and Sports, Myanmar·N/A·NCT07098728·180 enrolled

Encephalopathy1 trial

Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06851078·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Levetiracetam IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levetiracetam IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levetiracetam IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Levetiracetam IV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Seizure1 trial

Encephalopathy1 trial

References

Drug Info

Quick Facts

Related News